Your browser doesn't support javascript.
loading
Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics.
Partanen, Juulia J; Häppölä, Paavo; Zhou, Wei; Lehisto, Arto A; Ainola, Mari; Sutinen, Eva; Allen, Richard J; Stockwell, Amy D; Leavy, Olivia C; Oldham, Justin M; Guillen-Guio, Beatriz; Cox, Nancy J; Hirbo, Jibril B; Schwartz, David A; Fingerlin, Tasha E; Flores, Carlos; Noth, Imre; Yaspan, Brian L; Jenkins, R Gisli; Wain, Louise V; Ripatti, Samuli; Pirinen, Matti; Laitinen, Tarja; Kaarteenaho, Riitta; Myllärniemi, Marjukka; Daly, Mark J; Koskela, Jukka T.
Afiliación
  • Partanen JJ; Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
  • Häppölä P; Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
  • Zhou W; Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Lehisto AA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Ainola M; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Sutinen E; Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
  • Allen RJ; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Stockwell AD; Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
  • Leavy OC; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Oldham JM; Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
  • Guillen-Guio B; Department of Health Sciences, University of Leicester, Leicester, UK.
  • Cox NJ; Human Genetics, Genentech, South San Francisco, CA, USA.
  • Hirbo JB; Department of Health Sciences, University of Leicester, Leicester, UK.
  • Schwartz DA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Sacramento, CA, USA.
  • Fingerlin TE; Department of Health Sciences, University of Leicester, Leicester, UK.
  • Flores C; Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Noth I; Vanderbilt Genetic Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Yaspan BL; Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Jenkins RG; Vanderbilt Genetic Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Wain LV; Department of Medicine, University of Colorado, Aurora, CO, USA.
  • Ripatti S; Center for Genes, Environment and Health, National Jewish Health, Denver, CO, USA.
  • Pirinen M; Research Unit, Hospital Universitario Ntra. Sra. de Candelaria, Santa Cruz de Tenerife, Spain.
  • Laitinen T; Faculty of Health Sciences, University of Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain.
  • Kaarteenaho R; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
  • Myllärniemi M; Human Genetics, Genentech, South San Francisco, CA, USA.
  • Daly MJ; National Heart and Lung Institute, Imperial College London, London, UK.
  • Koskela JT; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Cell Genom ; 2(10): 100181, 2022 Oct 12.
Article en En | MEDLINE | ID: mdl-36777997
ABSTRACT
The research of rare and devastating orphan diseases, such as idiopathic pulmonary fibrosis (IPF) has been limited by the rarity of the disease itself. The prognosis is poor-the prevalence of IPF is only approximately four times the incidence, limiting the recruitment of patients to trials and studies of the underlying biology. Global biobanking efforts can dramatically alter the future of IPF research. We describe a large-scale meta-analysis of IPF, with 8,492 patients and 1,355,819 population controls from 13 biobanks around the globe. Finally, we combine this meta-analysis with the largest available meta-analysis of IPF, reaching 11,160 patients and 1,364,410 population controls. We identify seven novel genome-wide significant loci, only one of which would have been identified if the analysis had been limited to European ancestry individuals. We observe notable pleiotropy across IPF susceptibility and severe COVID-19 infection and note an unexplained sex-heterogeneity effect at the strongest IPF locus MUC5B.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies / Systematic_reviews Idioma: En Revista: Cell Genom Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies / Systematic_reviews Idioma: En Revista: Cell Genom Año: 2022 Tipo del documento: Article